AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Sphingosine 1-phosphate receptor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P21453

UPID:

S1PR1_HUMAN

Alternative names:

Endothelial differentiation G-protein coupled receptor 1; Sphingosine 1-phosphate receptor Edg-1

Alternative UPACC:

P21453; D3DT66; Q9BYY4; Q9NYN8

Background:

The Sphingosine 1-phosphate receptor 1 (S1P1), also known as Endothelial differentiation G-protein coupled receptor 1, plays a pivotal role in cell migration, heart development, angiogenesis, and immune function. It operates through G(i) proteins, activating several key pathways including RAC1, SRC, PTK2/FAK1, and MAP kinases. Its involvement in the reorganization of the actin cytoskeleton and lamellipodia formation is crucial for cell movement and response to sphingosine kinase SPHK1 activity.

Therapeutic significance:

Understanding the role of Sphingosine 1-phosphate receptor 1 could open doors to potential therapeutic strategies. Its critical functions in heart development, immune cell migration, and vascular maturation highlight its potential as a target in treating cardiovascular diseases, immune disorders, and promoting wound healing and tissue regeneration.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.